Arbutus biopharma and genevant sciences file patent infringement lawsuit against moderna

Warminster, pa., feb. 28, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and genevant sciences today filed a lawsuit in the u.s. district court for the district of delaware against moderna, inc. (nasdaq: mrna) and a moderna affiliate seeking damages for infringement of u.s. patent nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mrna-1273, moderna's vaccine for covid-19. the patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. the filed complaint is available on the arbutus website.
ABUS Ratings Summary
ABUS Quant Ranking